Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.45 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900840 | 1.00 | VNN1 (0.45) | VNN1DPP4PDK2DPP8HRH3 | |
| SCHEMBL5901127 | 1.00 | VNN1 (0.45) | VNN1DPP4PDK2DPP8HRH3 | |
| SCHEMBL3831586 | 0.89 | DPP4 (0.43) | VNN1DPP4PDK2DPP8HRH3 | |
| SCHEMBL8147960 | 0.87 | VNN1 (0.46) | VNN1DPP4PDK2DPP8HRH3 | |
| SCHEMBL2883536 | 0.82 | L3MBTL3 (0.50) | PDK2HRH3MCHR1USP30L3MBTL3 | |
| SCHEMBL21464535 | 0.82 | L3MBTL3 (0.50) | PDK2HRH3MCHR1USP30L3MBTL3 | |
| SCHEMBL2883532 | 0.82 | L3MBTL3 (0.50) | PDK2HRH3MCHR1USP30L3MBTL3 | |
| SCHEMBL21772872 | 0.82 | VNN1 (0.47) | VNN1DPP4DPP8USP30L3MBTL3 | |
| Hydrochloric Acid SCHEMBL3404368 | 0.81 | L3MBTL3 (0.49) | PDK2HRH3MCHR1USP30L3MBTL3 | |
| Hydrochloric Acid SCHEMBL3427002 | 0.81 | L3MBTL3 (0.49) | PDK2HRH3MCHR1USP30L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222290-B2 | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | SANOFI (FR) | 2012-07-17 | — | — | US | claimed |
| EP-2215058-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-11 | — | — | EP | claimed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| US-8222290-B2 | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | SANOFI (FR) | 2012-07-17 | — | — | US | disclosed |
| EP-2215058-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-11 | — | — | EP | disclosed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | HRH3, HRH4, UTS2R | VNN1 3240/4885DPP4 3252/4885PDK2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.